Teva Pharmaceutical Industries Ltd (TEVA:NYSE)
$33.77 0.15 (0.45%)
Analysed Teva Pharmaceutical Industries Ltd (TEVA:NYSE) News Sources
Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
Yahoo Finance
Teva Pharmaceutical Industries Ltd: Teva to Present at the Upcoming Investor Conferences in March
FinanzNachrichten.de
Teva to Present at the Upcoming Investor Conferences in March
Yahoo Finance
Teva Pharmaceutical Industries Ltd: U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV ...
FinanzNachrichten.de
Workiva (WK) Moves to Buy: Rationale Behind the Upgrade
Zacks.com on MSN
Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities
Insider Monkey on MSN
Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong Share Momentum
Kalkine Media
11 Best Strong Buy Healthcare Stocks to Invest In
Insider Monkey
Teva Pharmaceuticals seeks FDA greenlight for new schizophrenia treatment
Stocktwits on MSN
Sun Pharmaceutical Industries share price
Mint
What is the current price of Teva Pharmaceutical Industries Ltd (TEVA:NYSE)?
The current price of Teva Pharmaceutical Industries Ltd (TEVA:NYSE) is $33.77.
Teva Pharmaceutical Industries Ltd (TEVA:NYSE) absolute price change since previous trading day?
The absolute price change of Teva Pharmaceutical Industries Ltd (TEVA:NYSE) since the previous trading day is $0.15.
Teva Pharmaceutical Industries Ltd (TEVA:NYSE) percentage price change since previous trading day?
The percentage price change of Teva Pharmaceutical Industries Ltd (TEVA:NYSE) since the previous trading day is 0.45%.
What is This Week's average sentiment score for Teva Pharmaceutical Industries Ltd (TEVA:NYSE)?
This Week's average sentiment score for Teva Pharmaceutical Industries Ltd (TEVA:NYSE) is 81 out of 100.
What is This Week's average sentiment for Teva Pharmaceutical Industries Ltd (TEVA:NYSE)?
This Week's sentiment for Teva Pharmaceutical Industries Ltd (TEVA:NYSE) is .
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.